Kyverna Therapeutics Files 8-K
Ticker: KYTX · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1994702
Sentiment: neutral
Topics: corporate-disclosure, 8-K
TL;DR
Kyverna Therapeutics filed an 8-K on 12/15/25 with updated corporate info.
AI Summary
Kyverna Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 5980 Horton Street, Suite 550, Emeryville, California, 94608, with a business phone number of (510) 925-2492. The company is incorporated in Delaware and operates in the Biological Products sector.
Why It Matters
This 8-K filing provides updated corporate information and disclosures for Kyverna Therapeutics, Inc., which is important for investors and stakeholders to track the company's official communications and financial reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- December 15, 2025 (date) — Date of Report
- 5980 Horton Street, Suite 550, Emeryville, California, 94608 (location) — Principal Executive Offices
- (510) 925-2492 (phone_number) — Business Phone
- Delaware (jurisdiction) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically covering Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K filing submitted?
The filing was submitted on December 15, 2025.
Where are Kyverna Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 5980 Horton Street, Suite 550, Emeryville, California, 94608.
What is Kyverna Therapeutics, Inc.'s telephone number?
The company's telephone number, including area code, is (510) 925-2492.
In which state is Kyverna Therapeutics, Inc. incorporated?
Kyverna Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-12-15 06:30:11
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- d285116d8k.htm (8-K) — 24KB
- d285116dex991.htm (EX-99.1) — 31KB
- 0001193125-25-318377.txt ( ) — 179KB
- kytx-20251215.xsd (EX-101.SCH) — 3KB
- kytx-20251215_lab.xml (EX-101.LAB) — 18KB
- kytx-20251215_pre.xml (EX-101.PRE) — 11KB
- d285116d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: December 15, 2025 By: /s/ Marc Grasso, M.D. Marc Grasso, M.D. Chief Financial Officer